^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ewing Sarcoma
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/20/2020
    Excerpt:
    Ewing sarcoma: Second-line therapy (relapsed/refractory or metastatic disease)…Other Recommended Regimens…Cabozantinib